Ann: Botanix update on development pipeline products, page-4

Key highlights

• Completed pre-clinical testing of BTX 1801 - a novel antimicrobial with the potential to
address unmet needs in serious skin infections with significant market opportunities
• Pre-clinical testing indicated the BTX 1801 formulation achieved high levels of bacteria
killing effect compared with cannabidiol or PermetrexTM alone
• Target indications for BTX 1801 antimicrobial skin treatment being reviewed and
accelerated development pathway currently underway
• In addition, BTX 1308 pre-clinical study achieved primary objectives, and Botanix remains
on track to commence Phase 1b psoriasis patient study in 3Q CY2018